RU2721419C2 - Зонды визуализации белка гентингтина - Google Patents

Зонды визуализации белка гентингтина Download PDF

Info

Publication number
RU2721419C2
RU2721419C2 RU2018110055A RU2018110055A RU2721419C2 RU 2721419 C2 RU2721419 C2 RU 2721419C2 RU 2018110055 A RU2018110055 A RU 2018110055A RU 2018110055 A RU2018110055 A RU 2018110055A RU 2721419 C2 RU2721419 C2 RU 2721419C2
Authority
RU
Russia
Prior art keywords
carboxamide
dodeca
thia
methoxy
pentaene
Prior art date
Application number
RU2018110055A
Other languages
English (en)
Russian (ru)
Other versions
RU2018110055A3 (enExample
RU2018110055A (ru
Inventor
Селия Домингес
Джон ВИТЯК
Джонатан БАРД
Кристофер Джон Браун
Майкл Эдвард ПРАЙМ
Питер Дэвид ДЖОНСОН
Томас Мартин Крулл
Дэниел КЛАРК-ФРЮ
Дуэйн ХИГГИНС
Мэттью Роберт МИЛЛС
Ричард Уолдрон МАРСТОН
Сэмюэл КО
Саманта Луиз Джонс ГРИН
Сара ХЕЙЗ
Original Assignee
СиЭйчДиАй ФАУНДЕЙШН, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СиЭйчДиАй ФАУНДЕЙШН, ИНК. filed Critical СиЭйчДиАй ФАУНДЕЙШН, ИНК.
Publication of RU2018110055A publication Critical patent/RU2018110055A/ru
Publication of RU2018110055A3 publication Critical patent/RU2018110055A3/ru
Application granted granted Critical
Publication of RU2721419C2 publication Critical patent/RU2721419C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nuclear Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2018110055A 2015-08-28 2016-08-26 Зонды визуализации белка гентингтина RU2721419C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562211118P 2015-08-28 2015-08-28
US62/211,118 2015-08-28
PCT/US2016/049112 WO2017040336A1 (en) 2015-08-28 2016-08-26 Probes for imaging huntingtin protein

Publications (3)

Publication Number Publication Date
RU2018110055A RU2018110055A (ru) 2019-09-30
RU2018110055A3 RU2018110055A3 (enExample) 2019-10-28
RU2721419C2 true RU2721419C2 (ru) 2020-05-19

Family

ID=58103449

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018110055A RU2721419C2 (ru) 2015-08-28 2016-08-26 Зонды визуализации белка гентингтина

Country Status (18)

Country Link
US (3) US10137211B2 (enExample)
EP (1) EP3340796B1 (enExample)
JP (1) JP6944929B2 (enExample)
CN (1) CN108135172B (enExample)
AU (1) AU2016315648B2 (enExample)
BR (1) BR112018003331B1 (enExample)
CA (1) CA2995847C (enExample)
DK (1) DK3340796T3 (enExample)
ES (1) ES2885053T3 (enExample)
HR (1) HRP20211156T1 (enExample)
HU (1) HUE056509T2 (enExample)
IL (1) IL257537B (enExample)
MX (1) MX382156B (enExample)
PL (1) PL3340796T3 (enExample)
PT (1) PT3340796T (enExample)
RU (1) RU2721419C2 (enExample)
SI (1) SI3340796T1 (enExample)
WO (1) WO2017040336A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211778T1 (hr) 2014-08-29 2022-03-18 Chdi Foundation, Inc. Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina
SG11201701578YA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
SG11201701580XA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
PL3197277T3 (pl) 2014-08-29 2022-04-04 Chdi Foundation, Inc. Sondy do obrazowania molekularnego białka huntingtyny
CA2995847C (en) 2015-08-28 2024-05-28 Chdi Foundation, Inc. Probes for imaging huntingtin protein
WO2019157128A1 (en) 2018-02-08 2019-08-15 Phraxis Inc. End to end anastomotic connector
EP3749225A4 (en) * 2018-02-08 2021-11-17 Phraxis Inc. ONE-PIECE ANASTOMOTIC CONNECTOR
WO2020176424A1 (en) 2019-02-25 2020-09-03 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
IL298941A (en) * 2020-06-11 2023-02-01 Chdi Foundation Inc Heterocyclic compounds and imaging agents for the imaging of huntingtin protein
MX2023011888A (es) * 2021-04-08 2023-12-06 Chdi Foundation Inc Compuestos de isoindolinona y agentes de formación de imágenes para la obtencion de imágenes de la proteína huntingtina.

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639756A (en) * 1992-05-19 1997-06-17 Adir Et Compagnie Benzimidazole compounds
EA006199B1 (ru) * 2000-11-06 2005-10-27 Шеринг Акциенгезелльшафт Радиофармацевтические агенты для диагностики болезни альцгеймера
WO2007086800A1 (en) * 2006-01-27 2007-08-02 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
US20100098634A1 (en) * 2008-07-24 2010-04-22 Kolb Hartmuth C Imaging Agents Useful for Identifying AD Pathology
US20120070374A1 (en) * 2009-02-11 2012-03-22 Henriksen Gjermund Compounds for Non-Invasive Measurement of Aggregates of Amyloid Peptides
US8153796B2 (en) * 2007-08-02 2012-04-10 Sanofi-Aventis Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof
US20130302248A1 (en) * 2009-03-23 2013-11-14 Eli Lilly And Company Imaging Agents for Detecting Neurological Disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000351782A (ja) * 1999-04-06 2000-12-19 Yamanouchi Pharmaceut Co Ltd メタボトロピックグルタメート受容体作用薬及び新規チアゾロベンゾイミダゾール誘導体
AU2241400A (en) * 1999-04-06 2000-10-12 Yamanouchi Pharmaceutical Co., Ltd. Novel thiazolobenzoimidazole derivative
WO2005048953A2 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
HK1210732A1 (en) 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US9902702B2 (en) * 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
PL3197277T3 (pl) 2014-08-29 2022-04-04 Chdi Foundation, Inc. Sondy do obrazowania molekularnego białka huntingtyny
HRP20211778T1 (hr) 2014-08-29 2022-03-18 Chdi Foundation, Inc. Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina
SG11201701580XA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
SG11201701578YA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
CA2995847C (en) 2015-08-28 2024-05-28 Chdi Foundation, Inc. Probes for imaging huntingtin protein

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639756A (en) * 1992-05-19 1997-06-17 Adir Et Compagnie Benzimidazole compounds
EA006199B1 (ru) * 2000-11-06 2005-10-27 Шеринг Акциенгезелльшафт Радиофармацевтические агенты для диагностики болезни альцгеймера
WO2007086800A1 (en) * 2006-01-27 2007-08-02 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
US8153796B2 (en) * 2007-08-02 2012-04-10 Sanofi-Aventis Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof
US20100098634A1 (en) * 2008-07-24 2010-04-22 Kolb Hartmuth C Imaging Agents Useful for Identifying AD Pathology
US20120070374A1 (en) * 2009-02-11 2012-03-22 Henriksen Gjermund Compounds for Non-Invasive Measurement of Aggregates of Amyloid Peptides
US20130302248A1 (en) * 2009-03-23 2013-11-14 Eli Lilly And Company Imaging Agents for Detecting Neurological Disorders

Also Published As

Publication number Publication date
MX2018002338A (es) 2018-07-06
DK3340796T3 (da) 2021-07-26
US10137211B2 (en) 2018-11-27
US10765764B2 (en) 2020-09-08
US20210060187A1 (en) 2021-03-04
PT3340796T (pt) 2021-07-28
CA2995847C (en) 2024-05-28
IL257537B (en) 2020-08-31
HRP20211156T1 (hr) 2021-12-24
HUE056509T2 (hu) 2022-02-28
RU2018110055A3 (enExample) 2019-10-28
JP6944929B2 (ja) 2021-10-06
US20190167821A1 (en) 2019-06-06
MX382156B (es) 2025-03-13
CN108135172B (zh) 2021-03-30
AU2016315648A1 (en) 2018-03-29
EP3340796A4 (en) 2019-05-15
RU2018110055A (ru) 2019-09-30
US11344637B2 (en) 2022-05-31
PL3340796T4 (pl) 2022-02-21
CA2995847A1 (en) 2017-03-09
CN108135172A (zh) 2018-06-08
US20170056535A1 (en) 2017-03-02
SI3340796T1 (sl) 2022-02-28
PL3340796T3 (pl) 2022-02-21
AU2016315648B2 (en) 2021-04-01
EP3340796B1 (en) 2021-04-21
WO2017040336A1 (en) 2017-03-09
ES2885053T3 (es) 2021-12-13
EP3340796A1 (en) 2018-07-04
JP2018531897A (ja) 2018-11-01
IL257537A (en) 2018-04-30
BR112018003331B1 (pt) 2022-05-10
BR112018003331A2 (pt) 2018-11-06

Similar Documents

Publication Publication Date Title
US11344637B2 (en) Probes for imaging huntingtin protein
EP3186233B1 (en) Probes for imaging huntingtin protein
US12036291B2 (en) Probes for imaging huntingtin protein
EP3197277B1 (en) Probes for imaging huntingtin protein
EP3190888B1 (en) Probes for imaging huntingtin protein
HK1257113B (en) Probes for imaging huntingtin protein
HK1257113A1 (en) Probes for imaging huntingtin protein
HK40110855A (en) Probes for imaging huntingtin protein
HK1240582A1 (en) Probes for imaging huntington protein
HK1240582B (en) Probes for imaging huntington protein
HK1240583B (en) Probes for imaging huntingtin protein
HK1241223A1 (en) Probes for imaging huntingtin protein
HK1241223B (en) Probes for imaging huntingtin protein
HK1241224B (en) Probes for imaging huntingtin protein